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22.4° at 6weeks, p<0.001). The SPADI pain and disability 
score also indicated significant improvement in PRET arm at 
6 weeks when compared to standard arm (p < 0.05)  
 
Conclusion: Early institution of PRET program provides 
maximal benefit to the post surgical oral cancer patients 
undergoing RT than active exercises only and should be 
considered the standard of care. 
 
EP-1062  
Primary (chemo)radiation therapy in organ-sparing 
treatment of tongue squamous cell carcinoma 
A. Gevorkov
1Moscow Research Gerzen Oncology Institut, Radiation 
Oncology, Moscow, Russian Federation 
1, A. Boyko1 
 
Purpose or Objective: To evaluate the efficacy of primary 
(chemo)radiation therapy in a organ-sparing combined or 
radical nonsurgical treatment modality for tongue squamous 
cell carcinoma. 
 
Material and Methods: From January 2003 to January 2015 
166 consecutive patients with histologically proven the base 
(49 pts, 30%) and the mobile part of the tongue (MOT) cancer 
(117 pts, 70%) received radiotherapy +/- chemotherapy 
(concomitant) to the dose of 50Gy in the preoperative mode 
treatment and to 70Gy as radical irradiation. Most of them 
suffered from III (39%) and IV (35%) staged tumors, with the 
invasive nature of growth at 88 % and regional metastases in 
70%. Patients with base of tongue (BOT) cancer had locally 
advanced process more often (92% vs 66%), especially stage 
IV (69% vs 20%). Nonresectable process was diagnosed in 38% 
patients with BOT cancer and in 23% cases of MOT cancer 
primary tumor. We also assessed tumors for potential biologic 
predictors of treatment effectiveness (p53, COX-2 , VEGF, 
Ki67, E-cadherin , p21 , Bcl- 2 and others). Radiomodification 
with 5FU/cisplatin or cisplatin/cetuximab was performed in 
133 (80%) cases. All patients started with photon external 
beam radiation to the dose of 50Gy with subsequent decision 
of necessity of surgery by applying our prognostic model 
(combined clinical and biological predictive model with 
multivariate analysis, p<0,05). Nonsurgical treatment was 
performed in 56 (34%) cases. Patients with BOT primary 
tumor underwent conservative therapy more often (62% vs 
22%). Combined treatment with surgery was performed to 
110 (66%) patients, with the preservation of the organ in 76 
(69%) cases. Organ-sparing surgery was possible in 89 (76%) 
cases of MOT cancer and only in 16 (33%) cases of BOT 
cancer. 
 
Results: After irradiation we observed complete response in 
21% cases of BOT cancer and 7% of MOT cancer, partial 
response in 79% and 82% respectively. Stabilization and 
progression was diagnosed in 8% and 3% of cases MOT cancer. 
Complete morphological response in surgically removed 
tissues was obtained in 48% of BOT cancers and 22% of MOT 
cancers. 5-year general and disease-free survival were 70% 
and 58% respectively and there was not reliable difference 
between localizations. Surgical treatment for local relapse 
were performed 30 of 62 (48%) patients. 
 
Conclusion: In our single experience primary 
(chemo)radiation therapy has been shown to be feasible and 
resulted in high probability of organ-sparing treatment with 
reliable locoregional control, survival and better quality of 
life. 
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Purpose or Objective: Disease free survival and overall 
survival figures for early laryngeal cancer (T1) are excellent 
regardless of treatment modality used; either laser surgery or 
external beam radiotherapy. Randomised controlled trials of 
laser versus radiotherapy have failed to recruit. In comparing 
treatment modalities we must therefore look for other 
comparators including cost efficacy and patient reported 
outcomes (PROMS) . Voice outcomes are an important PROM 
in larynx cancer treatment. 
 
Material and Methods: A retrospective review of all patients 
treated at a regional Head and Neck centre over a 7 year 
period with T1a and T1b laryngeal cancers and subsequently 
followed up in the voice clinic. Patients were routinely asked 
to complete the Voice Handicap Index 10 (VHI-10) as part of 
standard care. The VHI-10 is an abbreviated version of the 
VHI which gives a subjective score of the degree of handicap 
experienced by the patient due to voice quality (Rosen 2004). 
The abbreviated score is validated and consistent. High 
scores indicate greater disability due to voice effects. VHI-10 
scores and data on disease status were collected. Patients 
were treated with either Type 1,2 or 3 carbon dioxide laser 
cordotomy (as per ELS classification) by a single surgeon or 
external beam radiotherapy to 55Gy in 20 fractions in 26 days 
with 6MV photons to a CT planned volume to the larynx only 
(no elective nodal irradiation)(PTV = CTV+5mm). Patients 
treated with radiotherapy usually had contraindications to 
laser surgery (tumour position or access). 
 
Results: 44 patients were identified with follow-up VHI data, 
30 of these had been treated with laser surgery (28 with T1a) 
and 14 with radiotherapy (8 with T1a). Mean follow up was 
3.01 years (0.5-5 years). Recurrence occurred in two patients 
after laser. One patient underwent further laser excision and 
the other received radiotherapy. There was 100% disease 
specific survival. The results were analysed by a General 
Linear Regression model with multiple imputations to address 
response gaps, using an SBS analysis tool. Both groups showed 
a statistically significant increase in mean VHI-10 scores over 
time and from pre-treatment baselines. VHI scores were 
higher for the radiotherapy treated cohort in the first year of 
follow up. Return to a VHI score of less than 10 was 6-9 
months for laser and 9-12 months for radiotherapy. 
Graph shows average VHI score from pre-treatment up to 62 
months post treatment. 
 
 
 
Conclusion: PROMs are an appropriate way to compare 
treatment modalities with similar disease outcomes. The VHI-
10 is an appropriate PROM for patients treated for laryngeal 
cancer. In an unselected retrospective population subjective 
voice outcomes are no worse with laser than with 
radiotherapy and therefore laser may be a preferred option 
due to lower cost and greater convenience. 
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Purpose or Objective: The treatment of choice for 
recurrences or second tumors of head and neck area, in areas 
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previously irradiated surgery is not always feasible. The poor 
results obtained exclusive chemotherapy.We have the 
objective to study treatment outcome in these tumors 
recurrent head and neck, previously irradiated. 
 
Material and Methods: We evaluated 57 patients with 
recurrent disease, between 2005 to 2014.27 larynx, 6 
nasopharynx,12 oropharynx, 6 hypopharynx and 6 oral cavity. 
The initial dose received between 50 and 70 Gy, 25/57 
received radical radiotherapy,17 /57 radical chemoradiation; 
other adjuvant radiotherapy, of which 8 / 57 was combined 
with chemotherapy. In 24 / 57 nodal recurrence (N1-N2), 
local 18/57 (T2-T4),6/57 local+nodal recurrence, 9/57 
seconds tumor,. Reirradiation with external 3D 
conforma/IMRTl techniques/ and dose between 50 Gy and 70 
Gy. Time between initial treatment and relapse: 11 to 72 
months. 
 
Results: 39/57 cases were complete response, 8 / 57 partial 
response, 7/57 stabilization, 3/57 progresion. Late toxicity: 
xerostomia (G: 2 26/57, G: 3 4/57), moderate fibrosis (6 /57, 
one case trismus), 2 osteoradionecrosis fistula required 
surgical treatment. Local control: 80%, median survival one 
year and 50% 2 years free of disease, two died of distant 
metastasis greater than 35 months after second treatment. 
 
Conclusion: This type of treatment, once considered 
contraindicated, after analyzing various authors, the 
potential has not seen a high incidence of severe damage 
expected in healthy tissues. Aggressive treatment of this 
disease recurring, allowing long survival, even in extensive 
disease is superior to best supportive care. 
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Purpose or Objective: Head and neck squamous cell 
carcinoma (HNSCC) is the 6th most common cancer 
worldwide, and both the disease and its treatment are 
associated with high morbidity. FDG-PET CT imaging can be 
performed approximately 12 weeks following IMRT to exclude 
persistent disease at the primary tumour site and/or local 
neck nodes. This report considers how post-treatment PET CT 
scans may be utilised to inform the follow up of patients 
treated for HNSCC.  
 
Material and Methods: A retrospective review of HNSCC 
patients treated with IMRT with radical intent between 
December 2010 and February 2013 and who underwent a 
post-treatment PET CT scan. Overall, relapse-free and loco-
regional relapse-free survival calculated from date of biopsy 
to date of death, relapse or last follow up. PET CT reports 
were noted and categorised as follows: 
‘Low-risk’ - normal scan  
‘Intermediate-risk’ – showing post-treatment change or 
inflammation  
‘High-risk’ – in keeping with or highly suspicious of residual 
disease 
 
Results: 100 patients were identified. Median follow up was 
2.8 years (range 58 days to 3.9 years). On review of PET CT 
reports, 47 patients were categorised as low-risk, 27 as 
intermediate-risk and 26 as high-risk. 13 of the 26 high-risk 
patients underwent a subsequent biopsy, with residual 
disease in 3. 6 of the 27 intermediate-risk patients 
underwent biopsy, with residual disease in 1.  
3-year overall survival was 93.3% (95% C.I. 80.7 to 97.8%) for 
the low-risk group, 79.3% (95% C.I. 56.7 to 91.0%) for the 
intermediate-risk group and 38.8% (95% C.I. 18.3 to 58.9%) 
for the high-risk group [p <0.0001].  
3-year relapse-free survival was 78.5% (95% C.I. 60.1 to 
89.1%) for the low-risk group, 74.0% (95% C.I. 50.1 to 87.7%) 
for the intermediate-risk group and 33.9% (95% C.I. 15.3 to 
53.6%) for the high-risk group [p <0.0001].  
3-year loco-regional relapse-free survival was 91.4% (95% C.I. 
78.6 to 96.7%) for the low-risk group, 81.6% (95% C.I. 56.5 to 
93.0%) for the intermediate-risk group and 71.5% (95% C.I. 
49.1 to 85.3%) for the high-risk group [p = 0.0310, figure]  
 
 
 
Conclusion: This report confirms the value of the 12-week 
post-treatment PET CT scan in identifying the risk of loco-
regional relapse and death following IMRT treatment for 
HNSCC. This information could be used to identify patients in 
a good prognostic group who may benefit from entering 
follow-up protocols aimed at addressing psychosocial and 
survivorship issues, with high-risk patients undergoing more 
intensive follow-up aimed at detecting relapse of disease. 
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Purpose or Objective: FDG-PET is perceived as a valuable 
diagnostic tool for patients with cancer of unknown primary 
(CUP). In the literature, detection rates are approximately 
30% for pooled patient populations. Patients with isolated 
neck lymph nodes of squamous cell carcinoma, are usually 
examined by an ENT specialist with panendoscopy, sampling 
blind biopsies, CT or MRI of the neck, sometimes ultrasound 
of the neck and a chest CT. After these examinations have 
been performed without finding the primary cancer, FDG-PET 
detection rates are reported to be approximately 25%. For 
our head and neck cancer patient population with CUP 
intended for definitive radiochemotherapy, we hypothesize 
that the previously reported FDG-PET detection rates are too 
high. 
 
Material and Methods: In our hospital during 2007-2013, 361 
head and neck cancer patients had an FDG-PET-CT 
examination in fixation mask as part of the radiotherapy 
treatment planning. In this group, 31 patients had cervical 
lymph node metastases of squamous cell carcinoma of 
unknown origin. 
 
Results: Two (cancer of the vallecula and esophagus) of 
these 31 patients had their primary cancer detected by FDG-
PET-CT giving a detection rate of 6.5% (95% C.I.: 2%, 21%). 
 
Conclusion: The FDG-PET detection rate of the primary 
cancer for patients with cervical lymph node metastases of 
squamous cell carcinoma, who have been through the 
standard diagnostic work-up, is lower than previously 
reported. FDG-PET may be less useful for this purpose than 
what has been anticipated. 
 
